# Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients

> **NCT01533922** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 295 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Placebo
- **DRUG:** Tiotropium
- **DRUG:** Olodaterol
- **DRUG:** tiotropium + olodaterol
- **DRUG:** Tiotropium + Olodaterol
- **DEVICE:** Respimat

## Key facts

- **NCT ID:** NCT01533922
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 295 (ACTUAL)
- **Last updated:** 2015-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01533922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01533922, "Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01533922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*